1. Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V. (October 2022) Authors: Gien, L.; Song, Z.; Poklepovic, A.; Collisson, E.A.; Mitchell, E.P.; Zweibel, J.A.; Harris, P.; Gray, R.J.; Wang, V.; McShane, L.M.; Rubinstein, L.V.; Patton, D.R.; Williams, P.M.; Hamilton, S.R.; Conley, B.A.; Arteaga, C.L.; Harris, L.N.; O'Dwyer, P.J.; Chen, A.P.; Flaherty, K.T. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. (October 2022) Authors: Reckamp, K.; Song, Z.; Gettinger, S.; Mitchell, E.P.; Wright, J.J.; Moscow, J.A.; Gray, R.J.; Wang, V.; McShane, L.M.; Rubinstein, L.V.; Patton, D.R.; Williams, P.M.; Hamilton, S.R.; Conley, B.A.; Arteaga, C.L.; Harris, L.N.; O'Dwyer, P.J.; Chen, A.P.; Flaherty, K.T. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗